Shionogi Hit By Surprise Japan Road Bump For Oral COVID Drug

After months of speculation and anticipation, Shionogi’s once-daily oral antiviral for the treatment of COVID-19 has stumbled after receiving an unexpected preliminary decision on its emergency approval from an advisory committee in Japan.

Shionogi faces further discussion for approval
Shionogi's oral COVID drug hits preliminary hurdle in Japan • Source: Shutterstock

Shionogi & Co. Ltd.’s share price plunged in morning trading in Tokyo on 23 June following a surprise decision the previous day from an advisory panel considering the emergency approval of its oral COVID-19 drug Xocova (ensitrelvir; S-217622).

The Japanese firm’s stock initially dropped around 10% following the meeting of the committee, which advises the Ministry of Health...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Japan

More from Focus On Asia